Kyowa Hakko Kirin Co., Ltd. - Product Pipeline Review - 2012

Summary

“Kyowa Hakko Kirin Co., Ltd. - Product Pipeline Review - 2012” provides data on the Kyowa Hakko Kirin Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Kyowa Hakko Kirin Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Kyowa Hakko Kirin Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Kyowa Hakko Kirin Co., Ltd. - Brief Kyowa Hakko Kirin Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Kyowa Hakko Kirin Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Kyowa Hakko Kirin Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Kyowa Hakko Kirin Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Kyowa Hakko Kirin Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Kyowa Hakko Kirin Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Kyowa Hakko Kirin Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Kyowa Hakko Kirin Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Kyowa Hakko Kirin Co., Ltd. and identify potential opportunities in those areas.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Kyowa Hakko Kirin Co., Ltd. Snapshot 7
Kyowa Hakko Kirin Co., Ltd. Overview 7
Key Information 7
Key Facts 7
Kyowa Hakko Kirin Co., Ltd. – Research and Development Overview 8
Key Therapeutic Areas 8
Kyowa Hakko Kirin Co., Ltd. – Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products – Monotherapy 14
Pipeline Products – Combination Treatment Modalities 15
Kyowa Hakko Kirin Co., Ltd. – Pipeline Products Glance 16
Kyowa Hakko Kirin Co., Ltd. – Late Stage Pipeline 16
Kyowa Hakko Kirin Co., Ltd. Clinical Stage Pipeline Products 18
Kyowa Hakko Kirin Co., Ltd. – Early Stage Pipeline Products 20
Kyowa Hakko Kirin Co., Ltd. – Drug Profiles 21
ARQ 197 + Erlotinib 21
ASKP-1240 23
bardoxolone methyl 24
brodalumab 26
darbepoetin alfa 28
fentanyl citrate 29
istradefylline 31
KHK-6188 33
KRN-23 34
KRN-330 35
KRN330 + Irinotecan 36
KW-0761 + mLSG15 37
KW-2450 40
KW-2450 + Lapatinib + Letrozole 41
KW-2478 43
KW-2478 + Bortezomib 44
KW-3357 45
KW-6356 47
litronesib 48
LY2523355 + Pegfilgrastim 50
MEDI-563 52
mogamulizumab 53
Onglyza 55
pegfilgrastim 57
salinomycin 58
tivantinib 60
tivozanib 62
topiramate 64
Kyowa Hakko Kirin Co., Ltd. – Pipeline Products by Route of Administration 65
Kyowa Hakko Kirin Co., Ltd. – Pipeline Products By Mechanism of Action 66
Kyowa Hakko Kirin Co., Ltd. – Recent Pipeline Updates 68
Kyowa Hakko Kirin Co., Ltd. - Dormant Projects 79
Kyowa Hakko Kirin Co., Ltd. - Discontinued Pipeline Products 80
Discontinued Pipeline Product Profiles 80
Kyowa Hakko Kirin Co., Ltd. – Company Statement 82
Kyowa Hakko Kirin Co., Ltd. – Locations And Subsidiaries 83
Head Office 83
Other Locations & Subsidiaries 83
Kyowa Hakko Kirin Co., Ltd., Recent Developments 86
Kyowa Hakko Kirin Co., Ltd.- Press Release 86
Financial Deals Landscape 101
Kyowa Hakko Kirin Co., Ltd., Deals Summary 101
Kyowa Hakko Kirin Co., Ltd., Pharmaceuticals & Healthcare, Deal Details 107
Asset Transactions 107
Venture Financing 111
Partnerships 114
Licensing Agreements 141
Equity Offering 229
Asset Transactions 231
Acquisition 232
Appendix 250
Methodology 250
Coverage 250
Secondary Research 250
Primary Research 250
Expert Panel Validation 250
Contact Us 251
Disclaimer 251

List of Tables
Kyowa Hakko Kirin Co., Ltd., Key Information 12
Kyowa Hakko Kirin Co., Ltd., Key Facts 12
Kyowa Hakko Kirin Co., Ltd. – Pipeline by Indication, 2012 15
Kyowa Hakko Kirin Co., Ltd. – Pipeline by Stage of Development, 2012 18
Kyowa Hakko Kirin Co., Ltd. – Monotherapy Products in Pipeline, 2012 19
Kyowa Hakko Kirin Co., Ltd. – Combination Treatment Modalities in Pipeline, 2012 20
Kyowa Hakko Kirin Co., Ltd. – Filed, 2012 21
Kyowa Hakko Kirin Co., Ltd. – Phase III, 2012 22
Kyowa Hakko Kirin Co., Ltd. – Phase II, 2012 23
Kyowa Hakko Kirin Co., Ltd. – Phase I, 2012 24
Kyowa Hakko Kirin Co., Ltd. – Pre-Clinical, 2012 25
Kyowa Hakko Kirin Co., Ltd. – Pipeline By Route of Administration, 2012 70
Kyowa Hakko Kirin Co., Ltd. – Pipeline Products By Mechanism of Action, 2012 72
Kyowa Hakko Kirin Co., Ltd. – Recent Pipeline Updates, 2012 73
Kyowa Hakko Kirin Co., Ltd. - Dormant Developmental Projects,2012 84
Kyowa Hakko Kirin Co., Ltd. - Discontinued Pipeline Products, 2012 85
Kyowa Hakko Kirin Co., Ltd., Other Locations 88
Kyowa Hakko Kirin Co., Ltd., Subsidiaries 89
Kyowa Hakko Kirin Co., Ltd., Deals Summary 106
ProStrakan Acquires Abstral From Orexo For $85 Million 112
ProStrakan Acquires Expanded Rights To Rectogesic and Tostran From Cellegy Pharma 114
Argos Therapeutics Secures $35 Million In Series C Financing 116
Anchor Therapeutics Enters Into Research Agreement With Kyowa Hakko Kirin 119
FUJIFILM Forms Joint Venture With Kyowa Hakko Kirin 121
Ferring Pharma Enters Into Co-Promotion Agreement With Kyowa Hakko For Desmopressin Acetate 123
BioWa Forms Joint Venture With Immunocellular 124
Kyowa Medex Enters Into Co-Marketing Agreement With Toyobo 125
Kyowa Hakko Enters Into Distribution Agreement With Hisamitsu Pharma 126
ProStrakan Enters Into Co-Marketing Agreement With EKR Therapeutics 127
Alnylam Pharma And Kyowa Hakko Form Alliance 128
Hisamitsu Pharma Enters Into An Agreement With Kyowa Hakko Kogyo 130
Chiome Bioscience Enters Into Research Agreement With Kyowa Hakko Kogyo 131
Arana Therapeutics Enters Into Agreement With Kyowa Hakko 132
BioWa Enters Into Strategic Research Collaboration Agreement With Lonza Group 133
ProStrakan Forms Partnership With NovaQuest 134
JapanBridge Enters Into Collaboration With Kyowa Hakko Kogyo 135
ProStrakan Signs An Agreement With LG Life Sciences 136
ProStrakan Forms Joint Venture With Orexo 137
Tillotts Pharma Enters Into Development And Marketing Agreement With Zeria And KYOWA HAKKO 138
Zeria Pharma Enters Into Co-Development Agreement With Kyowa Hakko Kogyo 139
DiaSorin Enters Into Distribution Agreement With Kyowa Medex 143
ProStrakan Enters Into Distribution Agreement With Gedeon Richter 144
Kyowa Hakko Kirin Enters Into Co-Development Agreement With Epistem 145
BioWa Enters Into Licensing Agreement With Otsuka Pharma 146
Biowa Enters Into Licensing Agreement With Sanofi-Aventis 147
Abeille Pharma Enters Into Licensing Agreement With Prostrakan 148
Lonza Enters Into Licensing Agreement With Kyowa Hakko And BioWa 151
ProStrakan Enters Into Licensing Agreement with Genus Pharma 152
Otsuka Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For Saxagliptin 153
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 155
arGEN-X Enters Into Licensing Agreement With Biowa 157
ImmunoCellular Therapeutics Enters Into Licensing Agreement With BioWa 158
Biowa Enters Into Licensing Agreement With Oxford BioTherapeutics 159
KaloBios Pharma Enters Into Licensing Agreement With BioWa And Lonza 161
Paladin Labs Enters Into Licensing Agreement With ProStrakan Group 162
Dicerna Pharma Expands Licensing Agreement With Kyowa Hakko 166
BioWa Enters Into Licensing Agreement With Agensys 167
H Lundbeck Enters Into Licensing Agreement With Kyowa Hakko Kirin For KW-6356 168
Daiichi Sankyo Enters Into Licensing Agreement With BioWa And Lonza 170
BioWa Expands Licensing Agreement With GlaxoSmithKline 172
BioWa Enters Into Licensing Agreement With GlaxoSmithKline For COMPLEGENT Technology 173
Biovail Labs International Enters Into Licensing Agreement With Kyowa Hakko Kirin 174
Solasia Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin 176
Reata Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin 180
Dicerna Enters Into Collaboration And License Agreement With Kyowa Hakko Kirin 182
Immunas Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin 183
BioWa Enters Into Licensing Agreement With NKT Therapeutics 184
Kyowa Hakko Enters Into Agreement With Yakult Honsha 185
BioWa Enters Into Licensing Agreement With Merck 186
Sanofi-Aventis Partners With Kyowa Hakko Kirin 187
Paladin Labs Enters Into Licensing Agreement With ProStrakan 189
Biowa Enters Into Licensing Agreement With GlaxoSmithKline 193
ProStrakan Enters Into License Agreement With NewBridge 194
BioWa Enters Into License Agreement With KaloBios Pharma 198
BioWa Enters Into Licensing Agreement With CSL 199
Orexo Extends Its Licensing Agreement With ProStrakan 200
Medarex Enters Into Licensing Agreement With BioWa 201
BioWa Enters Into Licensing Agreement With Novartis 202
ProStrakan Enters Into Licensing Agreement With JapanBridge 203
ProStrakan Enters Into Licensing Agreement With Torrex Chiesi Pharma 207
BAC Enters Into Licencing Agreement With Hematech 208
Amgen Enters Into Licensing Agreement With Kyowa Hakko Kirin 209
BioWa Expands Licensing Agreement With Genentech 211
LivTech Enters Into Licensing Agreement With Kyowa Hakko Kirin For LIV-1205 212
BioWa Enters Into Licensing Agreement With MedImmune 213
Biowa Enters Into Licensing Agreement With GlaxoSmithKline For POTELLIGENT Technology 214
Takeda Pharma Enters Into An Agreement With BioWa 215
Kyowa Hakko Kogyo Enters Into Licensing Agreement With ArQule 216
KYOWA HAKKO KOGYO Signs An Agreement With Life Science Pharma 218
UCB Enters Into Licensing Agreement With BioWa 220
MedImmune Enters Into Licensing Agreement With Biowa For BIW-8405 221
ProStrakan Enters Into Licensing And Distribution Agreement With Ferring 222
KYOWA HAKKO KOGYO Enters Into Licensing Agreement With Keryx BioPharma 223
ProStrakan Enters Into Licensing Agreement With Novartis 225
ProStrakan Enters Into Licensing Agreement With Amgen 227
ProStrakan Amends Licensing Agreement With Cellegy Pharma 229
BioWa Enters Into Licensing Agreement With Genentech 230
BioWa Enters Into Licensing Agreement With Aphton 231
Britannia Pharma Enters Into Licensing Agreement With Kyowa Hakko Kogyo 232
ProStrakan Completes Private Placement Of $20.8 Million 234
ProStrakan Sells Its Product Zindaclin To Crawford Healthcare 236
Kyowa Hakko Kirin Completes Acquisition Of ProStrakan 237
Kyowa Hakko Kirin Completes Sale Of Kyowa Hakko Chemical To Japan Industrial Partners 241
Norgine Acquires 12.61% Stake In ProStrakan 243
MDY Healthcare Acquires Minority Stake In ProStrakan Group 245
Dainippon Acquires Kyowa Hakko Pharma 247
Kyowa Hakko Kogyo Completes Acquisition Of Kirin Pharma 248
Kyowa Hakko Acquires Daiichi Fine Chemical 250
ProStrakan Group Sells ProSkelia To Galapagos 252
Kirin Acquires Remaining Shares Of Hematech 254

List of Figures
Kyowa Hakko Kirin Co., Ltd. – Pipeline by Indication, 2012 15
Kyowa Hakko Kirin Co., Ltd. – Pipeline by Stage of Development, 2012 18
Kyowa Hakko Kirin Co., Ltd. – Monotherapy Products in Pipeline, 2012 19
Kyowa Hakko Kirin Co., Ltd. – Combination Treatment Modalities in Pipeline, 2012 20
Kyowa Hakko Kirin Co., Ltd. – Pipeline By Route of Administration, 2012 70
Kyowa Hakko Kirin Co., Ltd. - Pipeline Products By Mechanism of Action, 2012 71